Search Results - "Dada, Adeshola"

N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor by Thomas, David R., Dada, Adeshola, Jones, Gareth A., Deisz, Rudolf A., Gigout, Sylvain, Langmead, Christopher J., Werry, Tim D., Hendry, Nicola, Hagan, Jim J., Davies, Ceri H., Watson, Jeannette M.

Get full text

N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M 1 receptor by Thomas, David R., Dada, Adeshola, Jones, Gareth A., Deisz, Rudolf A., Gigout, Sylvain, Langmead, Christopher J., Werry, Tim D., Hendry, Nicola, Hagan, Jim J., Davies, Ceri H., Watson, Jeannette M.

“…N-desmethylclozapine (NDMC) has been reported to display partial agonism at the human recombinant and rat native M 1 mAChR, a property suggested to contribute…”
Get full text

N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M sub(1) receptor by Thomas, David R, Dada, Adeshola, Jones, Gareth A, Deisz, Rudolf A, Gigout, Sylvain, Langmead, Christopher J, Werry, Tim D, Hendry, Nicola, Hagan, Jim J, Davies, Ceri H, Watson, Jeannette M

“…N-desmethylclozapine (NDMC) has been reported to display partial agonism at the human recombinant and rat native M sub(1) mAChR, a property suggested to…”
Get full text

In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics by DAWSON, Lee A, LANGMEAD, Christopher J, HILL, Mark D, JONES, Declan N. C, DAVIES, Ceri H, HAGAN, Jim J, SMITH, Paul W, DADA, Adeshola, WATSON, Jeannette M, ZINING WU, DE LA FLOR, Raúl, JONES, Gareth A, CLUDERAY, Jane E, SOUTHAM, Eric, MURKITT, Graham S

“…Clinical evaluation of tachykinin NK(3) receptor antagonists has provided support for the therapeutic utility of this target in schizophrenia. However, these…”
Get full text

In vitro and in vivo comparison of two non-peptide tachykinin NK sub(3) receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics by Dawson, Lee A, Langmead, Christopher J, Dada, Adeshola, Watson, Jeannette M, Wu, Zining, De la Flor, Raul, Jones, Gareth A, Cluderay, Jane E, Southam, Eric, Murkitt, Graham S, Hill, Mark D, Jones, Declan NC, Davies, Ceri H, Hagan, Jim J, Smith, Paul W

“…Clinical evaluation of tachykinin NK sub(3) receptor antagonists has provided support for the therapeutic utility of this target in schizophrenia. However,…”
Get full text

In vitro and in vivo comparison of two non-peptide tachykinin NK 3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics by Dawson, Lee A., Langmead, Christopher J., Dada, Adeshola, Watson, Jeannette M., Wu, Zining, de la Flor, Raúl, Jones, Gareth A., Cluderay, Jane E., Southam, Eric, Murkitt, Graham S., Hill, Mark D., Jones, Declan N.C., Davies, Ceri H., Hagan, Jim J., Smith, Paul W.

“…Clinical evaluation of tachykinin NK 3 receptor antagonists has provided support for the therapeutic utility of this target in schizophrenia. However, these…”
Get full text

N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor by Thomas, David R, Dada, Adeshola, Jones, Gareth A, Deisz, Rudolf A, Gigout, Sylvain, Langmead, Christopher J, Werry, Tim D, Hendry, Nicola, Hagan, Jim J, Davies, Ceri H, Watson, Jeannette M

“…N-desmethylclozapine (NDMC) has been reported to display partial agonism at the human recombinant and rat native M(1) mAChR, a property suggested to contribute…”
Get full text